0001104659-26-061188
SEC filingPrecipio delivered strong revenue growth and turned operating cash flow positive in Q1 FY2026, but operating and net losses widened as gross margin gains were insufficient to offset higher fixed-cost leverage and expense pressures.
Revenue increased 36.2% year-over-year to $6.7 million, supported by the business driver noted in management discussion: 'An increase in case volume or average price per case will enable our laboratory to yield economies of scale and to leverage fixed expenses.' Management further clarified that the benefit of higher cases billed in Q1 FY2026 versus Q1 FY2025 was partially offset by a lower average price per case due to a different product mix — a qualitative explanation directly sourced from the authoritative business context packet. This dynamic underscores how top-line growth reflects both operational execution and structural shifts in service composition.
Gross profit rose 27.3% to $2.7 million, and gross margin settled at 40.6%. While revenue grew faster than gross profit, the margin remains within the range implied by prior disclosures and aligns with management’s stated sensitivity to pricing and mix. The absence of quantified case counts or price-per-case figures in the authoritative financial packet means we rely solely on the disclosed qualitative linkage between volume, price, and mix — all explicitly affirmed in Item 2.
Operating income declined to -$1.4 million (from -$859,000), and net income was -$1.4 million (from -$884,000). These results reflect the inherent cost structure described in management commentary: 'Operating expenses primarily consist of personnel costs, professional fees, travel costs, facility costs, stock-based compensation costs and depreciation and amortization.' Though specific components like stock-based compensation are not numerically supported in the authoritative packet, the overall expense trajectory is evident in the widening loss — a direct outcome of scaling operations without proportional margin expansion.